PharmaCyte Biotech, Inc. financial metrics

Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q1 2026.

Symbol
PMCB on Nasdaq
Location
Las Vegas, NV
Fiscal year end
30 April
Latest financial report
17 Mar 2026

Quick Takeaways

  • PMCB - PharmaCyte Biotech, Inc. financial facts are built from SEC company filings data.
  • Latest metrics period on this page: Q1 2026.
  • Headline metric: Return On Equity -8.4%.

What Changed

  • Return On Equity YoY change: <span class="text-red-600">-115%</span>.
  • Most recent SEC facts end date: 12 Mar 2026.

Why This Matters

  • This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
  • Every metric card links to a deeper SEC-backed history page for verification.

Official SEC Source

Based on latest 10-Q/10-K

Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.

See Original Filing

Latest SEC snapshot (2026-03-12) highlights Return On Equity -8.4%, Return On Assets -6.6%, and Current Ratio 12.33x.

Financial Quality Score

Transparent 0-100 scoring model based on profitability, financial health, and growth factors.

21.0/100

Weak Confidence medium

Return On Equity

-8.4%

Metric score 0.0/100

Return On Assets

-6.6%

Metric score 0.0/100

Financial Health

Current Ratio
12.33x
Debt to Equity
0.24x

Strengths

Debt-to-equity

Watchpoints

Return On Equity, Return On Assets, and Current Ratio

Key metrics snapshot

Return On Equity

-8.4%

YoY: -115%

Industry median: -47% (n=218)

View history

Return On Assets

-6.6%

YoY: -119%

Industry median: -44% (n=217)

View history

Current Ratio

12.33x

YoY: -13%

Industry median: 3.67x (n=218)

View history

Debt-to-equity

0.24x

YoY: -27%

Industry median: 0.31x (n=169)

View history

NetIncomeLoss YoY

-116%

YoY:

Industry median: -12% (n=211)

View history

Profitability

Metric Latest value YoY change
Return On Equity -8.4% -115%
Return On Assets -6.6% -119%

Financial Health

Metric Latest value YoY change
Current Ratio 12.33x -13%
Debt-to-equity 0.24x -27%

Growth

Metric Latest value YoY change
Revenues $0
NetIncomeLoss YoY -116%

Share Metrics

Metric Latest value YoY change
Entity Common Stock, Shares Outstanding 10,735,649 +56%
Common Stock, Shares, Outstanding 10,735,649 +55%
Common Stock, Value, Issued $2,602 +20%
Weighted Average Number of Shares Outstanding, Basic 9,262,829 +33%
Weighted Average Number of Shares Outstanding, Diluted 9,262,829 +33%

Additional Metrics

Metric Latest value YoY change
Research and Development Expense $456,089 +12%
General and Administrative Expense $4,929,032 -32%
Operating Income (Loss) $5,385,121 +17%
Nonoperating Income (Expense) $2,103,493 -92%
Earnings Per Share, Basic -0.52 -172%
Earnings Per Share, Diluted -0.52 -172%
Cash and Cash Equivalents, at Carrying Value $20,165,535 +23%
Marketable Securities, Current $372,251 -0.1%
Assets, Current $20,696,450 +22%
Intangible Assets, Net (Excluding Goodwill) $1,549,427 0%
Assets $55,873,565 +27%
Accounts Payable, Current $1,200,082 +147%
Accrued Liabilities, Current $445,656 -37%
Liabilities, Current $1,678,229 +41%
Liabilities $16,471,229 +360%
Accumulated Other Comprehensive Income (Loss), Net of Tax $21,540 +12%
Retained Earnings (Accumulated Deficit) $100,000,171 -3.4%
Stockholders' Equity Attributable to Parent $38,113,013 -5.3%
Liabilities and Equity $55,873,565 +27%
Common Stock, Shares Authorized 200,000,000 0%
Common Stock, Shares, Issued 26,005,715 +20%
Common Stock, Par or Stated Value Per Share 0.0001 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $20,165,535 +23%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $3,278,682 -116%
Preferred Stock, Shares Authorized 10,000,000 0%
Additional Paid in Capital $183,141,663 +0.95%

How we score

This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.

Metric Weight V1 threshold
ROIC205% to 20%
ROE158% to 25%
ROA102% to 10%
Operating Margin55% to 25%
Current Ratio121.0x to 2.0x
Quick Ratio80.8x to 1.5x
Debt to Equity100.3x to 2.0x (lower is better)
Revenue YoY10-10% to +20%
Net Income YoY10-10% to +20%

How Calculated (standard_v1)

Metrics are computed with a market-consensus convention designed for cross-portal comparability.

  • TTM Operating Income / TTM Revenues
  • Current Assets / Current Liabilities (latest instant quarter)
  • (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
  • Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
  • TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
  • TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
  • TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
  • TTM Revenues YoY
  • TTM Net Income YoY